VEGFA and neoplasm: These include pairing ICIs with TKIs to normalize tumor vasculature and reduce VEGF-mediated suppression, combining ICIs with chemotherapy to increase tumor antigen release and DC activation, or using dual ICI regimens to target multiple immune checkpoints simultaneously.